SG3 Management’s Editas Medicine EDIT Stock Holding History

SG3 Management’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-19,025	Closed	-$505K	–	1084
2021 Q4	$505K	Sell	19,025 -63,475	-77%	-$2.18M	0.01%	621
2021 Q3	$3.39M	Buy	+82,500	New	+$4.52M	0.1%	197
2020 Q3	–	Sell	-87,386	Closed	-$2.85M	–	927
2020 Q2	$2.58M	Buy	87,386 +67,386	+337%	+$1.76M	0.18%	149
2020 Q1	$397K	Buy	+20,000	New	+$504K	0.05%	197

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

SG3 Management's EDIT Position: Q1 2022 in Review

SG3 Management sold out of Editas Medicine (EDIT) in Q1 2022, closing a stake of 19,025 shares — an estimated $505K sold.

SG3 Management first reported a position in EDIT in Q1 2020 and held it in 4 quarters. The position peaked at $3.39M in Q3 2021. 256 funds tracked by Wall St. Rank hold EDIT as of Q1 2022.

SG3 Management reported no remaining Editas Medicine position as of Q1 2022 after selling out during the quarter.
SG3 Management sold 19,025 Editas Medicine shares in Q1 2022, an estimated $505K.
SG3 Management first reported a position in Editas Medicine in Q1 2020 and held it in 4 quarters.
SG3 Management's Editas Medicine position peaked at $3.39M in Q3 2021.
256 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2022.

Based on SG3 Management's 13F filing for Q1 2022, filed 16 May 2022.